Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response
Abstract Background Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with metastatic MCC (mMCC). In mMCC, the response duration after cessation of ICIs treatment for com...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | JEADV Clinical Practice |
| Online Access: | https://doi.org/10.1002/jvc2.3 |